Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
Fernando C. Fervenza, Fan Fan Hou, Chuan‐Ming Hao, Gianna M. Kirsztajn et autres
BACKGROUND: Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab in patients with primary membranous nephropathy is needed. METHODS: In a phase …
us, cn, br, it, pl, ch, ca (code pays fourni par la source)
5 citations
New England Journal of Medicine